Evidence map›Paper›PMID 36896876›Full record

ArticleJournal of endovascular therapy : an official journal of the International Society of Endovascular Specialists2024

Intravascular Lithotripsy and Drug-Coated Balloon Angioplasty for Severely Calcified Common Femoral Artery Atherosclerotic Disease.

Konstantinos Stavroulakis, Giovanni Torsello, Gregory Chlouverakis, Theodosios Bisdas, Sarah Damerau, Nikolaos Tsilimparis, Angeliki Argyriou

Open access · hybridAbstract read
In one paragraph

Article in Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Konstantinos StavroulakisDepartment of Vascular Surgery, Ludwig-Maximilians-University Hospital Munich, Munich, Germany.ORCID 0000-0002-9775-9210
Giovanni TorselloDepartment of Vascular Surgery, St. Franziskus-Hospital GmbH, Münster, Germany.ORCID 0000-0001-7513-5063
Gregory ChlouverakisBiostatistics Laboratory, Department of Social Medicine, School of Medicine, University of Crete, Rethymno, Greece.
Theodosios BisdasDepartment of Vascular and Endovascular Surgery, Athens Medical Center, Marousi, Greece.
Sarah DamerauDepartment of Vascular Surgery, St. Franziskus-Hospital GmbH, Münster, Germany.
Nikolaos TsilimparisDepartment of Vascular Surgery, Ludwig-Maximilians-University Hospital Munich, Munich, Germany.
Angeliki ArgyriouDepartment of Vascular Surgery, Marien Hospital Herne, Herne, Germany.ORCID 0000-0002-8075-9695
Ludwig-Maximilians-Universität München · DESt. Franziskus Hospital · DEAthens Medical Center · GRUniversitätsklinik Marien Hospital Herne · DEUniversity of Crete · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesIntravascular lithotripsy (IVL) followed by drug-coated balloon (DCB) angioplasty might be a valuable alternative to surgery for calcified common femoral artery (CFA) atherosclerotic disease. Nonetheless, the 12 months performance of this treatment strategy remains unknown. This study reports on the 12 months outcomes of IVL with adjunctive DCB angioplasty for calcified CFA lesions.

methodsThis is a retrospective single-center, single-arm study. Consecutive patients treated by IVL and DCB for calcified CFA disease between February 2017 and September 2020 were evaluated. The primary measure outcome of this analysis was primary patency. Procedural technical success (<30% stenosis), freedom from target lesion revascularization (TLR), secondary patency, and overall mortality were additionally analyzed.

resultsThirty-three (n=33) patients were included in this study. The majority presented with lifestyle limiting claudication (n=20, 61%), 52% (n=17) of the patients had chronic kidney disease (CKD) and 33% (n=11) had diabetes. The procedural technical success was 97% (n=32). A flow-limiting dissection post IVL was observed in 2 patients (6%) and a peripheral embolization in a single patient (3%), while the bail-out stenting rate amounted to 12% (n=4). No perforation was observed. The median length of hospital stay was 2 days (interquartile range 2-3). At 12 months, the primary patency was 72%. The freedom from TLR and the secondary patency rates were 94% and 88%, respectively. The 12-month survival amounted to 100% and 75% (n=25) of the patients were asymptomatic or presented with mild claudication. The presence of chronic limb-threatening ischemia (CLTI) (hazard ratio [HR], 0.92; confidence interval (CI); 0.18-4.8, p=0.7) or CKD (HR, 1.30; 95% CI, 0.29-5.8; p=0.72), as well as the use of a 7 mm IVL catheter (HR, 0.59; 95% CI, 0.13-2.63; p=0.49) or of high-dose DCB (HR, 0.68; 95% CI, 0.13-3.53; p=0.65) did not influence the primary patency.

conclusionsIn this study, the combination of IVL and DCB angioplasty for calcified CFA disease was associated with low risk for periprocedural complications, acceptable 12 months clinical outcomes, and low rates of reinterventions. CLINICAL IMPACT: Intravascular lithotripsy in combination with DCB angioplasty can be an alternative to surgery in highly selected patients with CFA atherosclerotic disease. In this Cohort the combination therapy lead to acceptable clinical results and low reintervention rates at 12 months.

Indexed as

Angioplasty, BalloonCoated Materials, BiocompatibleFemoral ArteryLithotripsyPeripheral Arterial DiseaseVascular CalcificationVascular PatencyAgedAged, 80 and overCardiovascular AgentsCombined Modality TherapyFemaleHumansMaleMiddle AgedRetrospective StudiesCardiovascular AgentsCoated Materials, Biocompatiblecalcificationcommon femoral arterydrug-coated balloonlithotripsyperipheral arterial disease

Identifiers

PMID36896876
PMCPMC11552201
OpenAlexW4323809336

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.